Workflow
Cardiovascular disease
icon
Search documents
X @The Economist
The Economist· 2025-10-05 17:40
Dark chocolate’s purported benefits stem from compounds called flavanols, which can reduce the risk of cardiovascular disease.But the treat isn’t necessarily heart-healthy https://t.co/8iyzUMH7AI ...
Why your blood should flow like ketchup | Sean Farrington, PhD | TEDxWilmington
TEDx Talks· 2025-10-03 17:00
When I was a kid, my uncle would tell me these great stories about his aerospace engineering career. He used to tell me all about the machinery and the designs that he built throughout his life and always said he picked the perfect career for himself because of all the cool stuff he was able to build. Once he told me about working in the nose cone of an Apollo rocket, fixing some sensitive piece of equipment just a few days before its launch.I was enamored by this. Listening to his stories had me daydreamin ...
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
Globenewswire· 2025-09-28 15:15
Core Insights - Acoramidis has shown significant early and sustained clinical efficacy in reducing cumulative cardiovascular outcomes in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) [1][2][3] Group 1: Clinical Efficacy - Acoramidis reduced cumulative cardiovascular mortality (CVM) or recurrent cardiovascular-related hospitalizations (CVH) by 49% through Month 30 compared to placebo, with a p-value of less than 0.0001 [1][3] - At Month 30, 53 events were avoided per 100 treated participants, with a 95% confidence interval of 29 to 79 [1][3] - Continuous treatment with acoramidis at Month 42 resulted in a 45% reduction in CVM compared to a switch from placebo to acoramidis, with a p-value of 0.0011 [3] Group 2: Patient Population Insights - Acoramidis demonstrated a consistent mitigation of NT-proBNP levels in patients with variant ATTR-CM, starting from Month 3 and continuing through Month 30 [3] - The findings highlight the importance of early and continuous treatment with acoramidis, regardless of TTR genotype, in both wild-type and variant ATTR-CM patients [3] Group 3: Regulatory Approvals - Acoramidis is approved as Attruby® by the U.S. FDA and as BEYONTTRA® by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency [4][5] Group 4: Future Developments - Additional data on the benefits of Attruby for ATTR-CM patients is planned for future medical meetings [4]
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
Globenewswire· 2025-08-20 13:31
Core Insights - Novo Nordisk announced new data on the cardiovascular protective benefits of Wegovy and Ozempic, to be presented at the ESC Congress 2025, highlighting the role of inflammation in atherosclerotic cardiovascular disease (ASCVD) [1][3] Group 1: Cardiovascular Benefits - Semaglutide has been shown to reduce the risk of cardiovascular events by 20-26%, leading to fewer hospitalizations, heart attacks, strokes, and deaths among individuals with diabetes and obesity [2] - Novo Nordisk will present data demonstrating the unique benefits of semaglutide on heart and kidney disease, supported by both clinical trials and real-world evidence [4][6] Group 2: Symposium and Presentations - A symposium on the role of cardiovascular inflammation in ASCVD will take place on August 30, with various presentations scheduled throughout the congress, focusing on the effects of semaglutide in different patient populations [3][7] - Key presentations will include the impact of Wegovy on atrial fibrillation in obese individuals and new cardiometabolic benefits of Rybelsus and Ozempic in type 2 diabetes patients [6][7] Group 3: Company Overview - Novo Nordisk is a leading global healthcare company focused on chronic diseases, employing approximately 78,400 people and marketing products in around 170 countries [13]
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
GlobeNewswire News Room· 2025-08-20 13:31
Core Insights - Novo Nordisk announced new data on the cardiovascular protective benefits of Wegovy® and Ozempic® to be presented at the ESC Congress 2025, highlighting the role of inflammation in atherosclerotic cardiovascular disease (ASCVD) [1][3] Group 1: Cardiovascular Benefits - Semaglutide has been shown to reduce the risk of cardiovascular events by 20-26%, leading to fewer hospitalizations, heart attacks, strokes, and deaths for individuals with diabetes and obesity [2] - The unique benefits of semaglutide on heart and kidney disease will be substantiated through both clinical trials and real-world evidence at the ESC Congress [4] Group 2: Scientific Presentations - Key presentations will include data on Ozempic® (1.0 mg), Rybelsus® (oral semaglutide), and Wegovy® (2.4 mg), focusing on their impact on conditions like atrial fibrillation and cardiometabolic benefits in type 2 diabetes [5][6] - Specific sessions will address the effects of semaglutide on heart failure outcomes, cardiovascular risk factors, and the relationship between inflammation and cardiovascular events [6][13] Group 3: Research and Evidence - Real-world evidence will be presented to analyze the impact of inflammation on mortality and major cardiovascular events in individuals with ASCVD [3][5] - The role of systemic inflammation in cardiovascular disease and chronic kidney disease will be explored through various studies and analyses during the congress [13][19]
GLP-1s may help children reduce their risk of developing serious health conditions
NBC News· 2025-07-21 21:58
Potential Benefits of GLP-1s in Children - GLP-1s may offer cardiovascular benefits to children at high risk, similar to those observed in adults [2] - GLP-1s may reduce the risk of serious conditions like dementia, Alzheimer's, heart disease, and cancers in children, mirroring adult outcomes [1] Risks and Considerations - There is limited scientific data on the long-term effects of GLP-1s in children [1] Disease Progression in Children - Co-morbidities like pre-diabetes and cardiovascular disease risk can be more aggressive in children [2]
Tiny Hearts and Big Answers | Dr. Eman Akam-Baxter | TEDxYouth@DoverSherbornHighSchool
TEDx Talks· 2025-07-02 16:40
Cardiovascular Disease & Scar Tissue - Cardiovascular disease leads to one death every 33 seconds in the US, with scar tissue from heart attacks being a major cause [3][4] - Scar tissue, while preventing holes in the heart, impairs heart function, leading to heart failure as the heart muscle compensates for the non-functional scar tissue [6][7][8] - Unlike mammals, zebrafish can degrade scar tissue and regenerate heart tissue, despite the scar tissue being primarily composed of collagen [9][10] Collagen Cross-linking & TMRO Probe - The research indicates that the *type* of collagen cross-linking, rather than the *extent*, determines scar tissue degradability [32] - Mammalian scar tissue has "locked" collagen cross-links (specifically pyodenoline or PYD), making it difficult to degrade, while zebrafish have "open" cross-links [33][34][36][37] - The company developed a molecular imaging probe, TMRO, to detect collagen cross-linking, enabling reduced animal usage in research by visualizing the process [19][20][18] Fibrotic Diseases & Future Implications - This research has implications for fibrotic diseases, which account for 30-50% of deaths in the industrialized world, by potentially inhibiting the formation of "locked" collagen cross-links [37][38] - The company's mission is to inhibit the formation of these locks, allowing scar tissue to be degraded, restoring organ function, and preventing a large number of deaths [38]
Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Seeking Alpha· 2025-06-10 21:28
Core Insights - Amgen Inc. is experiencing positive momentum in its business as the first half of 2025 approaches its conclusion [3] - The company reported a 9% increase in first-quarter revenues and a 24% rise in non-GAAP EPS year-over-year, driven by strong performance across its product portfolio [4] - Fourteen products within Amgen's portfolio achieved double-digit growth in the first quarter of 2025 [4] Financial Performance - First-quarter revenues reached a growth of 9% year-over-year [4] - Non-GAAP EPS increased by 24% compared to the previous year [4] - Repatha, a key product, generated $656 million in revenue for Q1 2025, marking a 27% increase [4] Market Context - Cardiovascular disease continues to be a leading cause of mortality globally, which supports the ongoing demand for Amgen's products [5]